Christopher Kiritsy Sells 313 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the transaction, the director owned 250 shares of the company’s stock, valued at $39,250. This represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Palvella Therapeutics Trading Up 1.1%

PVLA opened at $157.24 on Friday. Palvella Therapeutics, Inc. has a 1-year low of $52.36 and a 1-year high of $161.38. The stock’s fifty day simple moving average is $148.35 and its 200 day simple moving average is $129.46. The stock has a market cap of $2.27 billion, a PE ratio of -32.55 and a beta of -0.25.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Equities analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, Chardan Capital raised shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $209.14.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds have recently bought and sold shares of the company. KBC Group NV bought a new position in Palvella Therapeutics in the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Palvella Therapeutics in the 2nd quarter valued at approximately $35,000. Group One Trading LLC boosted its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Palvella Therapeutics during the 3rd quarter valued at approximately $36,000. Finally, Archer Investment Corp bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at approximately $69,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.